190 related articles for article (PubMed ID: 22543678)
21. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma.
Alonso-Pérez A; Ballestero-Díez M; Fraga J; García-Díez A; Fernández-Herrera J
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1328-9. PubMed ID: 17062055
[No Abstract] [Full Text] [Related]
22. Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
Siegelmann-Danieli N; Bardo M; Law A; Fisk D; Bernath A
Isr Med Assoc J; 2004 Oct; 6(10):636-7. PubMed ID: 15473596
[No Abstract] [Full Text] [Related]
23. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
25. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
26. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
[No Abstract] [Full Text] [Related]
27. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
[TBL] [Abstract][Full Text] [Related]
28. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Wong SF; Jakowatz JG; Taheri R
Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
[TBL] [Abstract][Full Text] [Related]
29. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
30. Grand mal seizure induced by interferon-alpha-2b.
Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
[No Abstract] [Full Text] [Related]
31. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
Helbig D; Simon JC; Treudler R
Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
[No Abstract] [Full Text] [Related]
32. Vemurafenib-induced granuloma annulare.
Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
[No Abstract] [Full Text] [Related]
33. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
34. [High-dose interferon alpha in treatment of patients with malignant melanoma, monitoring of predictive and prognostic biomarkers].
Vanásková J; Grim J; Kopecký J; Kubala E; Filip S
Klin Onkol; 2011; 24(3):180-6. PubMed ID: 21717787
[TBL] [Abstract][Full Text] [Related]
35. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune response as a side effect of treatment with interferon-α in melanoma: does this have prognostic implications?
Palacios-Álvarez I; Román-Curto C; Mir-Bonafé JM; Cañueto J; Usero-Bárcena T; Fernández-López E
Int J Dermatol; 2015 Mar; 54(3):e91-3. PubMed ID: 25521221
[No Abstract] [Full Text] [Related]
37. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
38. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
[TBL] [Abstract][Full Text] [Related]
39. [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].
Assmann K; Nashan D; Grabbe S; Luger TA; Metze D
Hautarzt; 2002 Aug; 53(8):554-7. PubMed ID: 12221472
[TBL] [Abstract][Full Text] [Related]
40. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?
Radny P; Bauer J; Caroli UM; Eigentler TK; Kamin A; Metzler G; Garbe C
Dermatology; 2004; 209(3):249-50. PubMed ID: 15459547
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]